COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF)
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Documented diagnosis of heart failure (e.g., ICD-9 codes 428 ICD-10 codes I50 or Problem list in the electronic health record) Most recent EF assessed within the past 24 months Seen Mass General Brigham provider within the last 24 months English or Spanish speaking Exclusion Criteria: LVEF<50% currently prescribed or intolerant to both ARNi and SGLT2i LVEF>50% currently prescribed or intolerant to SGLT2i Systolic blood pressure (SBP) <90 mmHg at last measure Current severe aortic stenosis or severe aortic insufficiency Known amyloid heart disease Group 1 pulmonary arterial hypertension on disease-specific therapies (e.g., Ambrisentan, Bosentan, Epoprostenol, Treprostinil, Iloprost) eGFR<30 mL/min/1.73m2 Active chemotherapy Receiving end-of-life care or hospice History of transplant, currently listed above status 4 or being evaluated for transplant Outpatient intravenous inotrope use Current use of a Ventricular Assist Device Physician's discretion as inappropriate for remote management program
Sites / Locations
- Brigham and Women's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Medication & Education-First
Education-First
Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
Patient will first receive curated patient education, an alert to providers, and provider education, and then after 3 months begin participation in the remote heart failure clinic.